DTS-201 (sodium)

DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A) . DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer[1].

Product Specifications

CAS Number

[372491-73-1]

UNSPSC

12352209

Target

Aminopeptidase; Peptide-Drug Conjugates (PDCs)

Type

Peptides

Related Pathways

Antibody-drug Conjugate/ADC Related; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dts-201-sodium.html

Smiles

O=C(O[Na])CCC(NCCC(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@H]2C[C@@](C(CO)=O)(O)CC3=C2C(O)=C(C(C(C(OC)=CC=C4)=C4C5=O)=O)C5=C3O)C1)=O)=O)=O)=O)=O

Molecular Formula

C49H64N5NaO18

Molecular Weight

1034.04

References & Citations

[1]Ravel D, et al. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008, 14 (4), 1258–1265.